Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

[11] Van Belle S(2007)Antiemesis J Natl Compr Canc Netw 5 12-33

[12] Reinhardt RR(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570-1577

[13] Cohen L(1996)On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 189-195

[14] de Moor CA(2006)Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant J Support Oncol 4 403-408

[15] Eisenberg P(2004)Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261-2268

[16] De Jongh Garcia C(2008)How familiar are oncologists with therapeutic care and supportive care guidelines? Support Care Cancer 16 631-632

[17] Poli S(2008)Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting Cancer 112 2080-2087

[18] Ananth C(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112-4119

[19] De Wit R(2003)Treatment options for chemotherapy-induced nausea and vomiting: current and future Am J Cancer 2 391-392

[20] Eisenberg P(2008)Frequency and predictors of prescription-related issues after hospital discharge J Hosp Med 3 12-19

[11] Van Belle S(2007)Antiemesis J Natl Compr Canc Netw 5 12-33

[12] Reinhardt RR(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570-1577

[13] Cohen L(1996)On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993 Ann Oncol 7 189-195

[14] de Moor CA(2006)Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant J Support Oncol 4 403-408

[15] Eisenberg P(2004)Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261-2268

[16] De Jongh Garcia C(2008)How familiar are oncologists with therapeutic care and supportive care guidelines? Support Care Cancer 16 631-632

[17] Poli S(2008)Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting Cancer 112 2080-2087

[18] Ananth C(2003)The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112-4119

[19] De Wit R(2003)Treatment options for chemotherapy-induced nausea and vomiting: current and future Am J Cancer 2 391-392

[20] Eisenberg P(2008)Frequency and predictors of prescription-related issues after hospital discharge J Hosp Med 3 12-19